3-{4-(cholestan-3β-yl-oxymethyl)-[1,2,3]triazol-1-yl}propyl α-D-mannopyranosyl-(1-3)-α-D-mannopyranosyl-(1-2)-α-D-mannopyranoside | 1144492-24-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-{4-(cholestan-3β-yl-oxymethyl)-[1,2,3]triazol-1-yl}propyl α-D-mannopyranosyl-(1-3)-α-D-mannopyranosyl-(1-2)-α-D-mannopyranoside
• CAS: 1144492-24-9
• 化学式: C₅₁H₈₇N₃O₁₇
• 分子量: 1014.26
• InChiKey: DCTYUELVIXBIKT-FOQZHJEQSA-N

物化性质

• 沸点：
  1081.6±75.0 °C(predicted)
• 密度：
  1.52±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.14
• 重原子数：
  71.0
• 可旋转键数：
  20.0
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  297.62
• 氢给体数：
  10.0
• 氢受体数：
  20.0

反应信息

• 作为反应物：
  描述：

  3-{4-(cholestan-3β-yl-oxymethyl)-[1,2,3]triazol-1-yl}propyl α-D-mannopyranosyl-(1-3)-α-D-mannopyranosyl-(1-2)-α-D-mannopyranoside 在 三氧化硫吡啶 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 16.5h， 以94%的产率得到3-{4-(cholestan-3β-yl-methyl)-[1,2,3]triazol-1-yl}propyl 2,3,4,6-tetra-O-sulfo-α-D-mannopyranosyl-(1->3)-2,4,6-tri-O-sulfo-α-D-mannopyranosyl-(1->2)-3,4,6-tri-O-sulfo-α-D-mannopyranoside decasodium salt
  参考文献：
  名称：

  [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS

  摘要：

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。

  公开号：

  WO2009049370A1
• 作为产物：
  描述：

  3-{4-(cholestan-3β-yl-methyl)-[1,2,3]triazol-1-yl}propyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1->3)-2,4,6-tri-O-acetyl-α-D-mannopyranosyl-(1->2)-3,4,6-tri-O-acetyl-α-D-mannopyranoside 在 sodium methylate 作用下， 以 甲醇 为溶剂， 以97%的产率得到3-{4-(cholestan-3β-yl-oxymethyl)-[1,2,3]triazol-1-yl}propyl α-D-mannopyranosyl-(1-3)-α-D-mannopyranosyl-(1-2)-α-D-mannopyranoside
  参考文献：
  名称：

  Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis

  摘要：

  Increasing the aglycone lipophilicity of a series of polysulfated oligosaccharide glycoside heparan sulfate (HS) mimetics via attachment of a steroid or long chain alkyl group resulted in compounds with significantly improved in vitro and ex vivo antiangiogenic activity. The compounds potently inhibited heparanase and HS-binding angiogenic growth factors and displayed improved antitumor and antimetastatic activity in vivo compared with the earlier series. Preliminary pharmacokinetic analyses also revealed significant increases in half-life following iv dosing, ultimately supporting less frequent dosing regimens in preclinical tumor models compared with other HS mimetics. The compounds also displayed only mild anticoagulant activity, a common side effect usually associated with HS mimetics. These efforts led to the identification of 3 beta-cholestanyl 2,3,4,6-tetra-O-sulfo-alpha-D-glucopyranosyl- (1 -> 4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1 -> 4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1 -> 4)-2,3,6-tri-O-sulfo-beta-D-glucopyranoside, tridecasodium salt (PG545, 18) as a clinical candidate. Compound 18 was recently evaluated in a phase I clinical trial in cancer patients.

  DOI：

  10.1021/jm201708h